DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy

B. Hejdeman, A. C. Boström, R. Matsuda, S. Calarota, R. Lenkei, E. L. Fredriksson, E. Sandström, G. Bratt, B. Wahren

Research output: Contribution to journalArticlepeer-review


The aim of this study was to evaluate the immunological responses induced by DNA plasmids containing HIV regulatory genes administered in combination in HIV-1-infected patients with pretreatment with highly active antiretroviral treatment (HAART). The study is a double-blind, randomized, and placebo-controlled study, including 15 asymptomatic HIV-1-infected patients on stable HAART for at least 6 months and with plasma HIV RNA levels below 50 copies/ml. Ten patients received a combination of rev, tat, and nef intramuscularly (im) at weeks 0, 4, and 16 at increasing doses giving totals of 300 (100 x 3), 900 (300 x 3), and 1800 (600 x 3) μg DNA. Five patients received saline in the same amounts im. Antigen-specific cytotosic T lymphocyte (CTL) levels were preserved or increased and new T lymphocyte proliferative responses were induced in the group immunized with the HIV DNA genes. No increase in antibody levels was noted. Despite a 10-fold higher vaccine dose, patients on HAART did not respond better to vaccination compared to non-HAART patients included in a previous study where the genes were administered separately. Combining the regulatory genes rev, tat, and nef in increasing doses may reduce the anticipated augmentation of HIV-specific T cell proliferative and CTL responses. Viral suppression did not seem to further improve the initial vaccine responses of patients with comparable CD4 levels.

Original languageEnglish
Pages (from-to)860-870
Number of pages11
JournalAIDS Research and Human Retroviruses
Issue number8
Publication statusPublished - Aug 2004

ASJC Scopus subject areas

  • Immunology
  • Virology


Dive into the research topics of 'DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy'. Together they form a unique fingerprint.

Cite this